BACKGROUND: Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies that occur throughout the lifespan. The impact of age on disease features and outcome is unclear. METHODS: We analyzed the clinical features and outcome of all STS cases registered between 1973 and 2006 in the SEER database. RESULTS: There were 48,012 cases that met the selection criteria. Individuals less than 20 years of age represented 5.6%, with rhabdomyosarcoma being the most common subtype. In adults, the most common types were Kaposi sarcoma, fibrohistiocytic tumors, and leiomyosarcoma. Rhabdomyosarcoma was the only entity with a median age <20 years. Male predominance (male/female of 1.5:1) was noticed for almost all types of STS, except for alveolar soft part sarcoma and leiomyosarcoma. Tumor stage was similar across different age groups. Younger patients (<50 years) had significantly better survival than older patients (88.8 ± 0.2% vs. 40 ± 0.3%, P < 0.001), but for most histologies the survival decline with advancing age was gradual and did not occur abruptly at the onset of adulthood. The decline in survival with advancing age was particularly significant for rhabdomyosarcoma. CONCLUSION: With few exceptions, the clinical features of STS are similar in children and adults. However, individuals over 50 years of age have an inferior survival.
BACKGROUND:Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies that occur throughout the lifespan. The impact of age on disease features and outcome is unclear. METHODS: We analyzed the clinical features and outcome of all STS cases registered between 1973 and 2006 in the SEER database. RESULTS: There were 48,012 cases that met the selection criteria. Individuals less than 20 years of age represented 5.6%, with rhabdomyosarcoma being the most common subtype. In adults, the most common types were Kaposi sarcoma, fibrohistiocytic tumors, and leiomyosarcoma. Rhabdomyosarcoma was the only entity with a median age <20 years. Male predominance (male/female of 1.5:1) was noticed for almost all types of STS, except for alveolar soft part sarcoma and leiomyosarcoma. Tumor stage was similar across different age groups. Younger patients (<50 years) had significantly better survival than older patients (88.8 ± 0.2% vs. 40 ± 0.3%, P < 0.001), but for most histologies the survival decline with advancing age was gradual and did not occur abruptly at the onset of adulthood. The decline in survival with advancing age was particularly significant for rhabdomyosarcoma. CONCLUSION: With few exceptions, the clinical features of STS are similar in children and adults. However, individuals over 50 years of age have an inferior survival.
Authors: A A Hayes-Jordan; S L Spunt; C A Poquette; A M Cain; B N Rao; A S Pappo; S J Shochat Journal: J Pediatr Surg Date: 2000-06 Impact factor: 2.545
Authors: Darren J Little; Matthew T Ballo; Gunar K Zagars; Peter W T Pisters; Shreyaskumar R Patel; Adel K El-Naggar; Adam S Garden; Robert S Benjamin Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Iyad Sultan; Ibrahim Qaddoumi; Sameer Yaser; Carlos Rodriguez-Galindo; Andrea Ferrari Journal: J Clin Oncol Date: 2009-04-27 Impact factor: 44.544
Authors: Heather G Lyu; Leah A Stein; Lily V Saadat; Sheila N Phicil; Adil Haider; Chandrajit P Raut Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Rodrigo B Interiano; Sue C Kaste; Chenghong Li; Deo Kumar Srivastava; Bhaskar N Rao; William C Warner; Daniel M Green; Matthew J Krasin; Leslie L Robison; Andrew M Davidoff; Melissa M Hudson; Israel Fernandez-Pineda; Kirsten K Ness Journal: J Cancer Surviv Date: 2017-07-01 Impact factor: 4.442
Authors: Christopher L Tinkle; Israel Fernandez-Pineda; April Sykes; Zhaohua Lu; Chia-Ho Hua; Michael D Neel; Armita Bahrami; Barry L Shulkin; Sue C Kaste; Alberto Pappo; Sheri L Spunt; Matthew J Krasin Journal: Cancer Date: 2017-07-31 Impact factor: 6.860
Authors: Youssef Erfanian; Johannes Grueneisen; Julian Kirchner; Axel Wetter; Lars Erik Podleska; Sebastian Bauer; Thorsten Poeppel; Michael Forsting; Ken Herrmann; Lale Umutlu Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-31 Impact factor: 9.236
Authors: Sara M Federico; Sheri L Spunt; Matthew J Krasin; Catherine A Billup; Jianrong Wu; Barry Shulkin; Gerald Mandell; M Beth McCarville Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167